Off-Label Communications: US FDA Won't Impede Discussions With Payers, Gottlieb Says
Guidance, to be issued 'very soon,' will provide a safe harbor for discussions between manufacturers and payers about off-label drug uses, Commissioner Scott Gottlieb says.
You may also be interested in...
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.
US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.
Company discusses its strategy for negotiating a change in the recently-proposed Medicare coverage decision for Alzheimer’s drugs during a presentation to analysts.